| [1] |
Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson's disease: a systematic review and meta-analysis[J]. Mov Disord, 2014, 29(13):1583-1590.
|
| [2] |
Ma CL, Su L, Xie JJ, et al. The prevalence and incidence of Parkinson's disease in China: a systematic review and meta-an alysis[J]. J Neural Transm (Vienna), 2014, 121(2):123-134.
|
| [3] |
Fritsch T, Smyth KA, Wallendal MS, et al. Parkinson disease: research update and clinical management[J]. South Med J, 2012, 105(12):650-656.
|
| [4] |
Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins[J]. J Cell Biol, 1998, 143(7):1883-1898.
|
| [5] |
Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review[J]. JAMA, 2014, 311(16):1670-1683.
|
| [6] |
Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, et al. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia[J]. Mov Disord, 2008, 23(13):1889-1896.
|
| [7] |
Dewey RBJ. Autonomic dysfunction and management[J]//Pahwa R, Lyons KE. Handbook of Parkinson's disease[M]. 4th ed. New York: Dekker, 2007:77-91.
|
| [8] |
Kumar S, Bhatia M, Behari M. Sleep disorders in Parkinson's disease[J]. Mov Disord, 2002, 17(4):775-781.
|
| [9] |
Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease[J]. Eur J Neurol, 2013, 20(1):5-15.
|
| [10] |
Julius A, Longfellow K. Movement disorders: a brief guide in medication management[J]. Med Clin North Am, 2016, 100(4):733-761.
|
| [11] |
National Collaborating Centre for Chronic Conditions(UK). Parkinson's disease: national clinical guideline for diagnosis and management in primary and secondary care[J]. Royal College of Physicians (UK), 2006, PMID:21089238.
|
| [12] |
Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, et al. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study[J]. J Neurol, 2007, 254(4):459-464.
|
| [13] |
Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology[J]. Neurology, 2010, 74(11):924-931.
|
| [14] |
Schenck CH, Mahowald MW. Rapid eye movement sleep parasomnias[J]. Neurol Clin, 2005, 23(4):1107-1126.
|
| [15] |
Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease[J]. Mov Disord, 2009, 24(11): 1641-1649.
|
| [16] |
Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study[J]. Mov Disord, 2006, 21(7):916-923.
|
| [17] |
Diederich NJ, Vaillant M, Mancuso G, et al. Progressive sleep 'destructuring' in Parkinson's disease. A polysomnographic study in 46 patients[J]. Sleep Med, 2005, 6(4):313-318.
|
| [18] |
Mattis J, Sehgal A. Circadian rhythms, sleep, and disorders of aging[J]. Trends Endocrinol Metab, 2016, 27(4): 192-203.
|
| [19] |
Iranzo A, Tolosa E, Gelpi E, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study[J]. Lancet Neurol, 2013, 12(5):443-453.
|
| [20] |
Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson's disease-related pathology[J]. Cell Tissue Res, 2004, 318(1): 121-134.
|
| [21] |
Piccini P, Del Dotto P, Pardini C, et al. [Diurnal worsening in Parkinson patients treated with levodopa][J]. Riv Neurol, 1991, 61(6):219-224.
|
| [22] |
Placidi F, Izzi F, Romigi A, et al. Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients. An ambulatory polysomnographic study[J]. J Neurol, 2008, 255(7):1032-1037.
|
| [23] |
Haapaniemi TH, Pursiainen V, Korpelainen JT, et al. Ambulatory ECG and analysis of heart rate variability in Parkinson's disease[J]. J Neurol Neurosurg Psychiatry, 2001, 70(3): 305-310.
|
| [24] |
Kallio M, Suominen K, Haapaniemi T, et al. Nocturnal cardiac autonomic regulation in Parkinson's disease[J]. Clin Auton Res, 2004, 14(2):119-124.
|
| [25] |
Breen DP, Vuono R, Nawarathna U, et al. Sleep and circadian rhythm regulation in early Parkinson disease[J]. JAMA Neurol, 2014, 71(5):589-595.
|
| [26] |
Videnovic A, Lazar AS, Barker RA, et al. 'The clocks that time us'-circadian rhythms in neurodegenerative disorders[J]. Nat Rev Neurol, 2014, 10(12):683-693.
|
| [27] |
Videnovic A, Noble C, Reid KJ, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease[J]. JAMA Neurol, 2014, 71(4):463-469.
|
| [28] |
Aziz NA, Pijl H, Frolich M, et al. Diurnal secretion profiles of growth hormone, thyrotrophin and prolactin in Parkinson's disease[J]. J Neuroendocrinol, 2011, 23(6):519-524.
|
| [29] |
Aziz NA, Pijl H, Frolich M, et al. Leptin, adiponectin, and resistin secretion and diurnal rhythmicity are unaltered in Parkinson's disease[J]. Mov Disord, 2011, 26(4):760-761.
|
| [30] |
Kudo T, Loh DH, Truong D, et al. Circadian dysfunction in a mouse model of Parkinson's disease[J]. Exp Neurol, 2011, 232(1):66-75.
|
| [31] |
Sherin JE, Shiromani PJ, McCarley RW, et al. Activation of ventrolateral preoptic neurons during sleep[J]. Science, 1996, 271(5246):216-219.
|
| [32] |
Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle[J]. J Neurosci, 2005, 25(28): 6716-6720.
|
| [33] |
Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems[J]. J Neurosci, 1998, 18(23):9996-10015.
|
| [34] |
Carter ME, Yizhar O, Chikahisa S, et al. Tuning arousal with optogenetic modulation of locus coeruleus neurons[J]. Nat Neurosci, 2010, 13(12):1526-1533.
|
| [35] |
Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms[J]. Nature, 2005, 437(7063):1257-1263.
|
| [36] |
Hardin PE, Panda S. Circadian timekeeping and output mechanisms in animals[J]. Curr Opin Neurobiol, 2013, 23(5):724-731.
|
| [37] |
Honma S, Ono D, Suzuki Y, et al. Suprachiasmatic nucleus: cellular clocks and networks[J]. Prog Brain Res, 2012,199:129-141.
|
| [38] |
Aston-Jones G, Chen S, Zhu Y, et al. A neural circuit for circadian regulation of arousal[J]. Nat Neurosci, 2001, 4(7): 732-738.
|
| [39] |
Chou TC, Bjorkum AA, Gaus SE, et al. Afferents to the ventrolateral preoptic nucleus[J]. J Neurosci, 2002, 22(3):977-990.
|
| [40] |
Abrahamson EE, Leak RK, Moore RY. The suprachiasmatic nucleus projects to posterior hypothalamic arousal systems[J]. Neuroreport, 2001, 12(2):435-440.
|
| [41] |
Chou TC, Scammell TE, Gooley JJ, et al. Critical role of dorsomedial hypothalamic nucleus in a wide range of behavioral circadian rhythms[J]. J Neurosci, 2003, 23(33):10691-10702.
|
| [42] |
Mack JM, Schamne MG, Sampaio TB, et al. Melatoninergic system in Parkinson's disease: from neuroprotection to the management of motor and nonmotor symptoms[J]. Oxid Med Cell Longev, 2016, 2016:3472032.
|
| [43] |
Simonneaux V, Ribelayga C. Generation of the melatonin endocrine message in mammals: a review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters[J]. Pharmacol Rev, 2003, 55(2):325-395.
|
| [44] |
Moller M, Baeres FM. The anatomy and innervation of the mammalian pineal gland[J]. Cell Tissue Res, 2002, 309(1):139-150.
|
| [45] |
Terriff DL, Chik CL, Price DM, et al. Proteasomal proteolysis in the adrenergic induction of arylalkylamine-N-acetyltransferase in rat pinealocytes[J]. Endocrinology, 2005, 146(11):4795-4803.
|
| [46] |
Jockers R, Delagrange P, Dubocovich ML, et al. Update on melatonin receptors: IUPHAR Review 20[J]. Br J Pharmacol, 2016, 173(18):2702-2725.
|
| [47] |
Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions[J]. Endocr Rev, 1991, 12(2):151-180.
|
| [48] |
Pandi-Perumal SR, Srinivasan V, Maestroni GJ, et al. Melatonin: Nature's most versatile biological signal[J]? FEBS J, 2006, 273(13):2813-2838.
|
| [49] |
Arendt J. Melatonin and human rhythms[J]. Chronobiol Int, 2006, 23(1-2): 21-37.
|
| [50] |
Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance[J]. Biomed Pharmacother, 2006, 60(3): 97-108.
|
| [51] |
Choi SI, Dadakhujaev S, Ryu H, et al. Melatonin protects against oxidative stress in granular corneal dystrophy type 2 corneal fibroblasts by mechanisms that involve membrane melatonin receptors[J]. J Pineal Res, 2011, 51(1):94-103.
|
| [52] |
Franco DG, Markus RP. The cellular state determines the effect of melatonin on the survival of mixed cerebellar cell culture[J]. PloS One, 2014, 9(9):e106332.
|
| [53] |
Bondy SC, Sharman EH. Melatonin and the aging brain[J]. Neurochem Int, 2007, 50(4):571-580.
|
| [54] |
de Jonghe A, Korevaar JC, van Munster BC, et al. Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review[J]. Int J Geriatr Psychiatry, 2010, 25(12):1201-1208.
|
| [55] |
Fertl E, Auff E, Doppelbauer A, et al. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa[J]. J Neural Transm Park Dis Dement Sect, 1993, 5(3):227-234.
|
| [56] |
Adi N, Mash DC, Ali Y, et al. Melatonin MT1 and MT2 receptor expression in Parkinson's disease[J]. Med Sci Monit, 2010, 16(2):BR61-67.
|
| [57] |
Witkovsky P. Dopamine and retinal function[J]. Doc Ophthalmol, 2004, 108(1):17-40.
|
| [58] |
Serón-Ferré M, Torres-Farfán C, Forcelledo ML, et al. The development of circadian rhythms in the fetus and neonate[J]. Semin Perinatol, 2001, 25(6):363-370.
|
| [59] |
Shumay E, Fowler JS, Wang GJ, et al. Repeat variation in the human PER2 gene as a new genetic marker associated with cocaine addiction and brain dopamine D2 receptor availability[J]. Transl Psychiatry, 2012, 2:e86.
|
| [60] |
Roybal K, Theobold D, Graham A, et al. Mania-like behavior induced by disruption of CLOCK[J]. Proc Natl Acad Sci USA, 2007, 104(15):6406-6411.
|
| [61] |
Yujnovsky I, Hirayama J, Doi M, et al. Signaling mediated by the dopamine D2 receptor potentiates circadian regulation by CLOCK:BMAL1[J]. Proc Natl Acad Sci USA, 2006, 103(16):6386-6391.
|
| [62] |
Hood S, Cassidy P, Cossette MP, et al. Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors[J]. J Neurosci, 2010, 30(42):14046-14058.
|
| [63] |
Castaneda TR, de Prado BM, Prieto D, et al. Circadian rhythms of dopamine, glutamate and GABA in the striatum and nucleus accumbens of the awake rat: modulation by light[J]. J Pineal Res, 2004, 36(3):177-185.
|
| [64] |
McClung CA, Sidiropoulou K, Vitaterna M, et al. Regulation of dopaminergic transmission and cocaine reward by the Clock gene[J]. Proc Natl Acad Sci USA, 2005, 102(26):9377-9381.
|
| [65] |
Kawarai T, Kawakami H, Yamamura Y, et al. Structure and organization of the gene encoding human dopamine transporter[J]. Gene, 1997, 195(1):11-18.
|
| [66] |
Sleipness EP, Sorg BA, Jansen HT. Diurnal differences in dopamine transporter and tyrosine hydroxylase levels in rat brain: dependence on the suprachiasmatic nucleus[J]. Brain Res, 2007, 1129(1):34-42.
|
| [67] |
Paus S, Schmitz-Hubsch T, Wullner U, et al. Bright light therapy in Parkinson's disease: a pilot study[J]. Mov Disord, 2007, 22(10):1495-1498.
|
| [68] |
Terman M, Terman JS. Light therapy for seasonal and nonseasonal depression: efficacy, protocol, safety, and side effects[J]. CNS Spectr, 2005, 10(8):647-663.
|
| [69] |
Bogaerts V, Theuns J, van Broeckhoven C. Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria[J]? Genes Brain Behav, 2008, 7(2):129-151.
|
| [70] |
Mayo JC, Sainz RM, Uria H, et al. Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease[J]. J Pineal Res, 1998, 24(3):179-192.
|
| [71] |
Jin BK, Shin DY, Jeong MY, et al. Melatonin protects nigral dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity in rats[J]. Neurosci Lett, 1998, 245(2):61-64.
|
| [72] |
Bassani TB, Gradowski RW, Zaminelli T, et al. Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats[J]. Brain Res, 2014, 1593:95-105.
|
| [73] |
Yildirim FB, Ozsoy O, Tanriover G, et al. Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease[J]. Neurochem Int, 2014, 79:1-11.
|